Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Receivables (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Change in Receivables for 7 consecutive years, with $133000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Change in Receivables changed N/A year-over-year to $133000.0, compared with a TTM value of $170000.0 through Mar 2025, changed N/A, and an annual FY2023 reading of -$2.5 million, down 251.25% over the prior year.
  • Change in Receivables was $133000.0 for Q1 2025 at Bicycle Therapeutics, down from $49.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $49.9 million in Q3 2023 and bottomed at -$49.8 million in Q2 2023.
  • Average Change in Receivables over 4 years is -$477363.6, with a median of -$991000.0 recorded in 2022.
  • Peak annual rise in Change in Receivables hit 614.5% in 2023, while the deepest fall reached 582.14% in 2023.
  • Year by year, Change in Receivables stood at $1.0 million in 2021, then skyrocketed by 98.7% to $2.0 million in 2022, then soared by 2407.59% to $49.9 million in 2023, then crashed by 99.73% to $133000.0 in 2025.
  • Business Quant data shows Change in Receivables for BCYC at $133000.0 in Q1 2025, $49.9 million in Q3 2023, and -$49.8 million in Q2 2023.